Revvity (RVTY) Dropped, So What Is Catching Investors' Attention?

Revvity (RVTY) moved onto investor radar after recent trading left the shares around $143.45. Year-to-date total return figures and multi-year performance metrics provide a fuller picture of how the business has behaved.

Recent trading has been choppy for Revvity, with the share price slipping 2.24% over the last day after a strong 7-day share price return of 15.40% and a 90-day share price gain of 43.45%. The 1-year total shareholder return of 65.87% contrasts with a weaker 5-year total shareholder return that is down 20.62%, suggesting that momentum has picked up only in the more recent period.

Scan how Revvity’s recent surge compares to other health science players by checking out a curated set of 16 high quality undiscovered gems in the same broader space.

Revvity looks like a serious health sciences player, backed by growing revenue and net income, yet the share price has sprinted ahead in recent months. Is that business strength now fully reflected in the valuation, or not?

Most Popular Narrative: 9% Undervalued

The most followed narrative pegs Revvity’s fair value at $157.61, above the recent $143.45 close, which frames a modest valuation gap for investors to interrogate.

While consensus expects automation of key diagnostic assays and strong Signals software growth to support future revenue and margin, analysts broadly underappreciate the compounding effect of Revvity's record high software ARR growth, exceptional 115% net retention, and rapid SaaS transition. This pivot is expected to create a structurally higher, recurring-margin profile, driving sustained margin expansion and robust operating leverage over a multi-year horizon.

See why 1 investors see Revvity as 9% undervalued.

Result: Fair Value of $157.61 (UNDERVALUED)

Still, tighter regulation in regions like China and the EU, along with weak funding for key lab customers, could quickly weaken the bullish Revvity narrative.

Find out about the key risks to this Revvity narrative.

Another View: What Revvity’s P/E Ratio Is Telling You

The bullish fair value story around Revvity meets a very different message from simple price multiples. The stock trades on a P/E of 67.4x, compared with a fair ratio of 27.3x, a peer average of 41.1x and a global Life Sciences level of 37.4x. That gap points to meaningful valuation risk if sentiment cools or growth assumptions fade.

Numbers like these can help you stress test your own thesis on Revvity before committing fresh capital or doubling down on gains, especially when momentum has already been strong.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed feelings about Revvity after all that data are normal. The key is to review the numbers yourself and move quickly to frame your own stance. To see both the upside arguments and the issues that keep investors cautious, take a closer look at the 1 key reward and 1 important warning sign.

Looking for more Revvity-like investment ideas?

If Revvity has sharpened your curiosity, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities before they slip past you.

• Target resilient cash generators by reviewing companies in the list of solid balance sheet and fundamentals (23 results) that can better handle tougher trading conditions.
• Hunt for potential mispricings with the 33 high quality undervalued stocks and compare where expectations and current market prices look out of sync.
• Build a smoother ride for your portfolio by focusing on the 30 resilient stocks with low risk scores that score well on stability and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com